Evolving Paradigms in Axial Spondyloarthritis Management: A Review of Contemporary Treatment Strategies

Abstract

Objective: Axial spondyloarthritis (axSpA), encompassing ankylosing spondylitis and non-radiographic axSpA, is a chronic inflammatory disease that imposes a significant burden on patients through pain, stiffness, and potential long-term structural damage to the spine. This review synthesizes the current, state-of-the-art evidence on the management of axSpA, from foundational therapies to advanced biologic treatments and modern strategic approaches.

Methods: A comprehensive literature review was conducted, focusing on influential publications that shape the contemporary standard of care. Sources included the 2019 ACR/SPARTAN/SLR treatment recommendations, pivotal clinical trials, expert reviews on therapeutic mechanisms and outcomes, and meta-analyses of non-pharmacological interventions.

Results: The management of axSpA is built upon a foundation of non-pharmacological interventions, with strong evidence supporting the efficacy of structured exercise programs in improving physical function [8]. NSAIDs remain the first-line pharmacological treatment for symptom control [1]. For patients with an inadequate response to NSAIDs, biologic therapies, particularly TNF-α inhibitors (anti-TNFs), have revolutionized care by providing substantial and rapid improvements in disease activity and quality of life [2, 4]. However, their ability to definitively halt radiographic progression remains a subject of investigation, with structural damage persisting as a key concern [3]. More recent advances include the approval of drugs with different mechanisms of action, such as IL-17 and JAK inhibitors [7]. Furthermore, there is a paradigm shift towards goal-oriented strategies like Treat-to-Target (T2T), an approach validated by the TICOSPA trial, which demonstrated superior outcomes with a tight-control protocol [5, 6].

Conclusion: The therapeutic landscape for axSpA has evolved dramatically, moving beyond simple symptom relief towards a multi-faceted, goal-directed approach. The integration of non-pharmacological methods, established pharmacotherapies, and strategic management frameworks offers the potential to significantly improve patient outcomes. Preventing long-term structural damage, however, remains the critical unmet need guiding future research.